Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 5, pp. 481-481
Open Access | Times Cited: 925

Showing 1-25 of 925 citing articles:

Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1402-1411
Open Access | Times Cited: 987
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 18, pp. 1637-1648
Open Access | Times Cited: 635
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 953-953
Open Access | Times Cited: 414
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Ling-Xiao Shao, Clara Liao, Ian Gregg, et al.
Neuron (2021) Vol. 109, Iss. 16, pp. 2535-2544.e4
Open Access | Times Cited: 367
The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
David B. Yaden, Roland R. Griffiths
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 568-572
Open Access | Times Cited: 364
Novel and emerging treatments for major depression
Steven Marwaha, Edward Palmer, Trisha Suppes, et al.
The Lancet (2022) Vol. 401, Iss. 10371, pp. 141-153
Open Access | Times Cited: 304
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 296
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 17
Open Access | Times Cited: 259
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
Manoj K. Doss, Michal Považan, Monica D. Rosenberg, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 228
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Charles L. Raison, Gerard Sanacora, Joshua D. Woolley, et al.
JAMA (2023) Vol. 330, Iss. 9, pp. 843-843
Open Access | Times Cited: 224
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
Robin von Rotz, Eva Maria Schindowski, Johannes Jungwirth, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101809-101809
Open Access | Times Cited: 223
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 173
Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Friederike Holze, Peter Gasser, Felix Müller, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 3, pp. 215-223
Closed Access | Times Cited: 170
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
Jacob S. Aday, Alan K. Davis, Cayla M. Mitzkovitz, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 424-435
Open Access | Times Cited: 167
The neural basis of psychedelic action
Alex C. Kwan, David E. Olson, Katrin H. Preller, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1407-1419
Closed Access | Times Cited: 166
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 153
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Nakul Ravi Raval, Annette Johansen, Lene Lundgaard Donovan, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 835-835
Open Access | Times Cited: 147
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
Mario de la Fuente Revenga, Bohan Zhu, Christopher A. Guevara, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109836-109836
Open Access | Times Cited: 147
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Laura Ley, Felix Müller, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 6, pp. 1180-1187
Open Access | Times Cited: 147
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis, et al.
Brain (2021) Vol. 145, Iss. 2, pp. 441-456
Open Access | Times Cited: 143
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 140
The promises and perils of psychedelic pharmacology for psychiatry
Tristan McClure‐Begley, Bryan L. Roth
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 463-473
Closed Access | Times Cited: 139
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
A. Becker, Friederike Holze, Tanja Grandinetti, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 886-895
Open Access | Times Cited: 130
Page 1 - Next Page

Scroll to top